Fighting Cancer

Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit
vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • miami-herald_logo2

    Vigilant Biosciences cleared to launch its oral cancer test across Europe

    Vigilant Biosciences, an early-stage Fort Lauderdale-based company that develops solutions that aid in the early detection and intervention of cancer, announced that it has CE Marked its OncAlert Oral Cancer RAPID Test, meaning it can market the product in the…more

  • sunsentinel

    Fort Lauderdale company’s cancer test receives European marketing approval

    Vigilant Biosciences, a startup company in Fort Lauderdale, has received European Commission approval to market its oral cancer testing product. European approval to sell the product “is a major milestone for our company as it enables us to initiate manufacturing…more

  • vb-400x210

    Vigilant Biosciences Receives CE Mark for OncAlert™ Oral Cancer RAPID Test to Aid in Diagnosis of Oral Cancer

    First and Only Rapid Test to Detect a Tumor-initiating and Stem Cell Associated Biomarker for Head and Neck Cancer FORT LAUDERDALE, Fla. – May 4, 2016 – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid…more

  • logo

    National Consumer Survey Reveals Greater Need for Oral Cancer Education and Prevention

    This year alone, more than 600,000 new cases of oral cancer will be detected worldwide, including over 48,000 Americans. In the U.S. this year, there will be 9570 deaths from this disease—roughly 1 person per hour, every day. This is…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×